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Abstract
Understanding how nanoparticles may affect immune responses is an essential prerequisite to developing novel clinical
applications. To investigate nanoparticle-dependent outcomes on immune responses, dendritic cells (DCs) were treated with
model biomedical poly(vinylalcohol)-coated super-paramagnetic iron oxide nanoparticles (PVA-SPIONs). PVA-SPIONs
uptake by human monocyte-derived DCs (MDDCs) was analyzed by ﬂow cytometry (FACS) and advanced imaging
techniques. Viability, activation, function, and stimulatory capacity of MDDCs were assessed by FACS and an in vitro
CD4+ T cell assay. PVA-SPION uptake was dose-dependent, decreased by lipopolysaccharide (LPS)-induced MDDC
maturation at higher particle concentrations, and was inhibited by cytochalasin D pre-treatment. PVA-SPIONs did not alter
surface marker expression (CD80, CD83, CD86, myeloid/plasmacytoid DC markers) or antigen-uptake, but decreased the
capacity of MDDCs to process antigen, stimulate CD4+ T cells, and induce cytokines. The decreased antigen processing and
CD4+ T cell stimulation capability of MDDCs following PVA-SPION treatment suggests that MDDCs may revert to a more
functionally immature state following particle exposure.
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Introduction
The development of novel nanotechnology-based
pharmaceutical compounds has been constantly
increasing over recent years, with some products
already approved for clinical use. Although more
than 200 biomedical nanomaterials were estimated
to be under development in the year 2006 (deﬁned as
a material that has one or more external dimensions in
the nanoscale) no guidelines exist to date that specif-
ically regulate synthesis and testing of these products,
for human use (Powers 2006; International Organi-
zation for Standardization [ISO] 2008). Recently,
both European and US regulatory agencies have
provided recommendations to address utilization
of nanotechnology-based biomedical products in
humans (European Medicines Agency [EMEA]
2006; U.S. Food and Drug Administration [FDA]
2007).
Super-paramagnetic iron-oxide nanoparticles
(SPIONs) represent a versatile and multi-functional
class of promising biomedical nanoparticles that
combine advantageous properties of an inorganic
metal core with speciﬁcally designed functionality of
a biocompatible polymer shell (Boyer et al. 2010). The
particle surface confers outstanding properties to
SPIONs and nanoparticles in general, including sta-
bilization in biological ﬂuids (colloids), or speciﬁc cell
targeting to enhance drug or gene delivery. These
unique physico-chemical properties, together with
super-paramagnetism, provide many useful advantages
for existing diagnostic clinical areas such as magnetic
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resonance imaging (MRI), as well as for novel
biomedical approaches with therapeutic drug or gene
delivery, tissue engineering, and bio-separation
(Laurent et al. 2008).
One of the major difﬁculties in the development of
appropriate biomedical nanoparticles for speciﬁc
clinical applications is our current deﬁcit in the
understanding of how nanoparticles may inﬂuence
immune responses (Dobrovolskaia and McNeil
2007; Dobrovolskaia et al. 2009). Despite an impor-
tant body of epidemiological and experimental
research on ambient particulate matter and engi-
neered nanoparticles that has addressed conventional
toxicological aspects, it is not possible at present to
predict immune and inﬂammatory responses a spe-
ciﬁc type and size of nanoparticle may trigger
(Oberdörster et al. 2005; Maynard et al. 2006;
Dobrovolskaia and McNeil 2007). Several factors
lie behind this lack of knowledge: With few excep-
tions, physico-chemical properties of nanoparticles
(e.g. surface charge), their shell characteristics (poly-
mer type), and behaviour in different colloidal
solutions have not been systematically characterized
to date, especially with respect to interaction with
immune cells (Foged et al. 2005; Dobrovolskaia
and McNeil 2007). Furthermore, for the synthesis of
nanoparticles destined for biomedical applications, a
great deal of differences in the rawmaterials employed
and lack of standardized manufacturing processes
have rendered comparison between nanoparticles
from different research groups problematical.
The immunological properties of nanoparticles
may be broadly determined by characteristics related
to antigenicity, adjuvant behaviour, generation of
inﬂammatory mediators, predominant internalization
pathway(s), and immune cell type(s) most likely
encountered (Chen et al. 1998; Dobrovolskaia and
McNeil 2007; Manolova et al. 2008; Klippstein and
Pozo 2010). In general, nanoscale drugs and diag-
nostic compounds are either being speciﬁcally
designed for immunomodulation through their inter-
action with the immune system (e.g. nano-vaccines),
or these formulations are speciﬁcally engineered to
evade recognition by the immune system. For both
situations, clarifying how nanoscale compounds inter-
act with the immune system is crucial in order to
understand which key characteristics of these
compounds determine immune responses and to
improve their design for future therapeutic or diag-
nostic applications (Dobrovolskaia and McNeil 2007;
Dobrovolskaia et al. 2008, 2009).
The administration of drugs via mucosal surfaces
(i.e. respiratory or gastro-intestinal tract) is attractive
for reasons such as accessibility, needle-free admin-
istration, and site-speciﬁc action. Epithelia at the
interfaces between the organism and environment
are endowed with antigen-presenting cells (APC)
that constantly scrutinize incoming antigen. There-
fore, for the development of appropriate nanoscale
compounds delivered to mucosal environments, their
interaction with most frequently encountered APC,
including DCs, macrophages and B cells, requires
careful clariﬁcation. DCs are known to be the most
specialized APC type, capable of presenting antigen to
naïve T cells in the lymph nodes through cognate
interactions, and thus are fundamental in orchestrat-
ing both innate and adaptive immune responses. DCs
are primarily localized near the interfaces between
body surfaces and the environment, where they con-
tinuously assess incoming antigen and particulate
matter for the potential danger they may represent
for the organism (Holt and Stumbles 2000). For
example, the large mucosal surface area of the respi-
ratory tract is continuously exposed to large amounts
of antigen and particulate matter, and DCs form a
tightly enmeshed mucosal network localized in the
epithelium of conducting airways and lung paren-
chyma. This localization enables continuous scrutiny
of inhaled antigen or particulates, either inducing
tolerance to inoffensive substances, or initiating
immunity against allergens or potentially harmful
pathogens (von Garnier et al. 2005). A prerequisite
for immunological homeostasis at this site are strin-
gent control mechanisms to protect the vital and
exquisitely fragile gaseous exchange barriers from
damage that an exaggerated immune response to an
innocuous allergen may cause (von Garnier and
Nicod 2009). During DC activation, there is
up-regulation of co-stimulatory molecules, matura-
tion markers, and chemokine receptor CCR7 that
enables DC migration to regional lymph nodes for
activation of naïve T cells. DC activation is also
accompanied by chemokine and cytokine release
that not only serves to amplify innate immune
responses, but also determines the type of effector
T cell population and net immune response gener-
ated. Given the importance of DCs as sentinel cells in
regulating innate and adaptive immune functions,
studying functional changes that DCs may undergo
when exposed to nanoscale compounds is central to
understanding the impact on subsequent mucosal
immune responses. We herein report our results
obtained from a robust in vitro pre-clinical mono-
cyte-derived human DCs (MDDCs) model that was
utilized to assess immune effects of prototypical bio-
medical SPIONs. Studies were performed on imma-
ture MDDCs or on MDDCs cultured in the presence
of lipopolysaccharide (LPS) to mature the cells and
simulate inﬂammatory changes in the microenviron-
ment. The ﬁndings obtained with this approach may
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have important implications when designing speciﬁc
immunomodulatory properties of novel biomedical
nanoparticles.
Materials and methods
Nanoparticle synthesis, labelling, and characterization
Reagents. All reagents were of analytical reagent grade
and utilized without further puriﬁcation. Polyvinyl
alcohol PVA (Mowiol 3–85), with an average molec-
ular weight (MW) of 14,000 g/mol and a hydrolysis
degree of 85%, was supplied by courtesy of KUR-
ARAY (Kuraray Specialties Europe GmbH,
65926 Frankfurt/ Main, Germany). Vinyl alcohol/
vinyl amine copolymer M12, with an average MW
of 80,000–140,000, was supplied by courtesy of
SEKISUI (Sekisui Specialty Chemicals Europe,
43080 Tarragona, Spain). Polymer solutions were
prepared by dissolving the powders in water followed
by rapidly heating and subsequent ﬁltration of the hot
solutions over paper ﬁlters (Schleicher & Schuell
AG). Ultrapure deionized water (Seralpur delta
UV/UF setting, 0.055 S/cm) was used in all synthesis
steps. D-9527 Sigma cellulose membrane dialysis
tubing with a molecular weight cut-off at 12,000
was used for dialysis.
Particle size. Light scattering measurements were per-
formed at 90 on a photon correlation spectrometer
(PCS) from Brookhaven equipped with a BI-9000AT
digital auto-correlator. The CONTIN method was
used for data processing. The concentration of iron
oxide nanoparticles was set to 100 mg iron/ml for all
measurements. The theoretical refractive index of
2.42 of magnetite was used to calculate the number
weighted distribution from the raw intensity weighted
data. Zeta-potential measurements were performed
using the same setting, equipped with a platinum
electrode. The electrode was cleaned for 10 min in
an ultrasonic bath prior to each measurement and
pre-equilibrated for 2 min in an aliquot of the sample.
Viscosity, refractive index, and dielectric constant of
pure water were used to characterise the solvent.
Superparamagnetic iron oxide nanoparticles (SPIONs).
Nanoparticle synthesis and characterization were per-
formed as previously described (Petri-Fink and
Hofmann 2007). Brieﬂy, SPIONs were prepared by
alkaline co-precipitation of ferric and ferrous
chlorides in aqueous solution (Bee et al. 1995;
Chastellain et al. 2004). The obtained precipitate
was washed several times with ultrapure water and
the remaining solid was reﬂuxed in nitric acid (10 M)
in the presence of Iron-(III)-nitrate (FLUKA). The
resulting suspension was dialysed against 0.01 M
nitric acid (FLUKA) for two days, and stored at 4C.
Polymer-coated particles. Polymer-coated SPIONs
were produced as described elsewhere (Petri-Fink
et al. 2005). Magnetic nanoparticles were stabilized
by a mixture of polyvinyl alcohol (Mowiol 3–85) and
vinyl alcohol/vinyl amine copolymer (M12, vinyl
alcohol/vinyl alcohol copolymer mass ratio). The
product will be referred to as PVA-SPION. The
iron content of the suspension was determined by
redoxtitration. In order to quantify the amount of
surface adsorbed polymer, a colorimetric assay was
developed based on the polyvinyl alcohol-iodine-
boric acid complex (Baumgartner 1987). The assay
was carried out in a 96-well plate and absorbance of
yellow-green complexes was read at 668 nm by a
TECAN plate reader (TECAN, Inﬁnite).
Fluorochrome coupling and SPION characterization.
Surface derivatization of PVA-coated SPIONs was
performed in the previously described magnetic bed
reactor (Steitz et al. 2007). Brieﬂy, PVA-SPIONs
were loaded and immobilized in the reactor. Dye
coupling was achieved by re-circulating 250 mg Ore-
gon green (Oregon green protein labelling kit
(F6153), Invitrogen) or 100 mg Alexa 680 (Alexa
680 carboxylic acid, succinimidyl ester (A20008),
Invitrogen), respectively, in 0.1 M carbonate buffer
(pH 9.5) over immobilized nanoparticles for 2–4 h
with a ﬂow rate of 2.5 ml/min. After the reaction, free
dye was removed before re-circulating 0.1 M lysine in
0.1 M carbonate buffer (pH 9.5) for 1 h at a ﬂow rate
of 2.5 ml/min. Excess lysine was removed by extensive
washing with PBS (pH 7.4). In a ﬁnal step, functio-
nalized particles were eluted from the magnetic reac-
tor and extensively characterized before and after dye
coupling (Table I). Following dye coupling, the iron
Table I. Summary of particle properties before and after dye
coupling.
Parameters
PVA-
SPIONs
OG-PVA-
SPIONs
Alexa-PVA-
SPIONs
Iron conc. [mg/ml] 4.4 1 1
PVA conc. [mg/ml] 22.1 4.5 7.9
Dye conc. [mg/ml] - 1.5 8.6
Dye molecules/particle - ~40 ~6
Size [nm] 29.4 ± 4.1 122.1 ± 14.6 117.0 ± 8.17
Zeta potential [mV] +16.7 ± 1.5 +6.7 ± 2.2 +5.6 ± 1.2
pH 7.2 7.4 7.3
Particles/ml [1010] 9 2 2
OG, Oregon green; Alexa, Alexa Fluor 680.
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concentration was set to 1 mg/ml by dilution in PBS.
After dye coupling, the polymer/iron ratio was slightly
decreased, most likely due to extensive puriﬁcation of
ﬁnal particles in the reactor leading to loss of surface
stabilizing macromolecules (i.e. PVA) that causes a
relatively important increase in particle size (Table I).
Although the augmented particle size is mainly
attributable to the presence of dye molecules, a certain
degree of agglomeration within the ﬁnal preparation
cannot be entirely excluded. Nevertheless, the PVA-
SPIONs utilized for all subsequent investigations
were highly colloidally stable in all solutions (e.g.
cell culture media) and environments tested (Petri-
Fink and Hofmann 2007). The zeta potential (surface
charge) decreased from +16.7 mV to +6.7 mV, indi-
cating signiﬁcant coupling of both Oregon green and
Alexa Fluor 680 ﬂuorochromes to amine groups of
the polymer coating. The zeta potential of derived
particles remained slightly positive, which was proven
to be very helpful to enable cellular internalization in
previous studies (Petri-Fink et al. 2005). Combina-
tion of a speciﬁcally designed polymer coating for
SPIONs (e.g. PVA) with a ﬂuorescence label there-
fore provided nanoparticles with both a “tracking
signal” (ﬂuorescence signal and electron-dense iron
oxide core) and a potential afﬁnity for targeted cell
types (MDDCs). Labelled PVA-SPIONs destined for
in vitro cell experiments were stored in PBS at an iron
concentration of 1 mg/ml at 4C and utilized within
two weeks. To ensure that SPIONs were endotoxin-
free, particles preparations were regularly tested using
the Limulus Amebocyte Lysate (LAL) assay (Lonza,
Walkersville, MD, USA) performed according to the
manufacturer’s speciﬁcations. None of the particle
batches tested was found to contain endotoxin
(data not shown).
Human monocyte-derived DC cultures, maturation and
SPION exposure
Peripheral blood mononuclear cells (PBMC) were
obtained from buffy coats provided by healthy blood
donors (Regional Red Cross Blood Donation Centre,
Bern, Switzerland) by Ficoll-Paque (Amersham, Bios-
ciences) density centrifugation. Monocytes were
isolated from PBMC by CD14 positive selection uti-
lizing the MACS microbeads (Miltenyi Biotech) as
per manufacturer protocol to a purity of >95%. The
CD14 negative fraction was frozen and kept for T cell
stimulation assays (see autologous CD4+ T cell stim-
ulation assay). MDDCs were generated by culturing
in RPMI 1640 medium (Invitrogen) containing
10% FCS, (Amimed/BioConcept), 1% L-glutamine
(2 mM; Invitrogen), 1% penicillin/streptomycin
(100 U/ml; Invitrogen), 10 ng/ml GM-CSF (R&D
Systems), and 10 ng/ml IL-4 (R&D Systems) for six
days at 37C in a 5% CO2 humidiﬁed atmosphere as
previously described (Sallusto and Lanzavecchia
1994). All reagents utilized were endotoxin-free as
per manufacturer standard. To induce matura-
tion, MDDCs were stimulated during 12 h with
100 ng/ml LPS (Sigma-Aldrich) as previously
described and exposed during 12 h to SPIONs that
were pre-diluted in PBS, cautiously sonicated dur-
ing 2 min, and directly re-suspended in the cell cul-
ture medium at indicated ﬁnal concentrations
(Regamey et al. 2007).
Flow cytometry (FACS)
Unless indicated otherwise, antibodies were obtained
from eBioscience. Staining was strictly performed on
ice throughout the entire procedure. Cells were incu-
bated with anti-Fc block (anti-human CD16/CD32;
BD Pharmingen) to reduce non-speciﬁc binding
10 min prior to addition of the following anti-human
Abs: PE-conjugated anti-CD11c and -CD123, PE-
Cy7-conjugated HLA-DR, biotinylated anti-CD11b
-CD80, -CD83, -CD86, -BDCA1 (BD Pharmingen),
-BDCA2 (BD Pharmingen). Relevant isotype control
antibodies were used throughout. Streptavidin-
conjugated ﬂuorochromes, allophycocyanin, PerCP,
FITC, PE, and PerCP cyanin 5.5 were purchased
from eBioscience. Cell samples were analyzed for sur-
face ﬂuorescence by ﬂow cytometry using a LSRII (BD
Biosciences). Unless indicated otherwise, staining for
surfacemolecules was reported as the frequency of cells
expressing the marker of interest. Endocytotic capacity
(antigen uptake) and antigen processing were mea-
sured by incubation with a variety of ﬂuorescent
conjugates, as previously described (Wikstrom et al.
2006; von Garnier et al. 2007). OVA-Alexa Fluor
647 (Molecular Probes) was utilized to measure endo-
cytotic capacity and DQ-OVA (Molecular Probes) to
determine antigen processing. MDDCs were incu-
bated during a time course of 0–120 min at 37C or
on ice (controls) to measure antigen uptake and pro-
cessing. Propidium iodide (Invitrogen) and annexin V
(eBioscience) staining was performed to determine cell
death and apoptosis, respectively. Cells frozen for
30 min at 70C or ﬁxed with formaldehyde 4% for
30min at room temperature, served as positive controls
for propidium iodide and annexin V staining, respec-
tively (data not shown). FACS data was analyzed using
FlowJo (Tree Star).
Autologous CD4+ T cell stimulation assay
Autologous CD4+ T cells were negatively selected
from the CD14 negative fraction (see above,
4 F. Blank et al.
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monocyte isolation) utilizing MACS microbeads
(Miltenyi Biotech) as per manufacturer protocol to
a purity of 98%. After washing, 10 – 103 MDDCs
(1.0  102 to 1.0  104 cells/ml) stimulated with
LPS and/or exposed to both PVA-SPION concentra-
tions were incubated with 104 CD4+ T cells (1.0 
105 cells/ml) at DCs to CD4+ T cell ratios of
1:1000 – 1:10 in 96 well tissue culture plates contain-
ing 200 ml of medium per well. Tetanus toxoid
(Calbiochem) was used as antigen at a concentration
of 0.5 mg/ml. Unless indicated otherwise, the results
with the 1:10 DC:CD4+ T cell ratio are shown.
Co-cultures were performed for ﬁve days and pulsed
with 0.5 mCi [3H] thymidine (Amersham Biosciences)
during the last 16 h. The incorporated radio-
activity was measured using a liquid scintillation
counter. A separate culture plate without radio-
activity was utilized for cytokine determination in
the supernatants.
Cytokine assays
Cell culture supernatants from autologous CD4+
T cell stimulation assays were analyzed utilizing a
Luminex multiplex array system (Bio-Rad) for
IL-1b, IL-6, IL-10, IL-12p70, IFNg, and TNFa,
according to manufacturer protocol.
Quantiﬁcation of endocytosed SPIONs and
co-localization by laser scanning microscopy (LSM)
and image restoration
MDDCs were treated with PVA-SPIONs (10 and
20 mg/ml) during 4 h and subsequently incubated
with Transferrin Alexa 633 (100 mg/ml; marker for
lysosomes) for 20 min either in the absence or pres-
ence of cytochalasin D (Cyt-D; 10 mg/ml) added to
the cell cultures 30 min before particle exposure as
previously described (Thiele et al. 2001). Cells were
ﬁxed in 2.5% glutaraldehyde and processed for TEM
(see below). For the analysis by LSM, cells were
washed in phosphate-buffered saline (PBS, 10 mM,
pH 7.4: 130 mMNaCl, Na2HPO4, KH2PO4) and
ﬁxed for 15 min at room temperature in 3% parafor-
maldehyde in PBS. Fixed cells were treated with
0.1 M glycine in PBS for 5 min and permeabilized
in 0.2% Triton X-100 in PBS for 15 min. Cells were
stained with rhodamine phalloidin 1:100 (R-415;
Molecular Probes, Invitrogen AG, Basel, Switzer-
land) and with DAPI (1 mg/ml) for 1 h at room
temperature.
Optical sections were taken using a Zeiss LSM
510Meta with an inverted Zeiss microscope (Axiovert
200M; lasers: HeNe 633 nm, HeNe 543 nm, Ar
488 nm, and a 405 nm diode laser; Carl Zeiss AG,
Feldbach, Switzerland) with a Plan-Apochromat
63 1.4 objective and an optical zoom of 3.5.
The resulting voxel size was 0.08  0.08 
0.25 mm. Image processing, particle visualization
and co-localization with lysosomes was performed
with IMARIS (Bitplane AG, Zurich, Switzerland),
a three-dimensional multi-channel image processing
software for confocal microscopic images. To visual-
ize the labelled MDDCs, a rendering mode was used
that displays the maximum intensity projection (i.e.
the maximum intensity of all layers along the viewing
direction) of the recorded three-dimensional stack.
After image acquisition, the total particle number and
the number of particles co-localized with lysosomes
were counted with the particle tracker software Dia-
count (Semasopht, Lausanne, Switzerland). In each
experimental sample the cells were randomly scanned
by LSM. Experiments were performed in triplicate or
quadruplicate and 10 or more cells were scanned per
data point. Since LSM is not able to resolve SPIONs
size, counted particles and co-localization were
expressed as particle events and co-localized events,
respectively with events referring to the number of
voxels emitting signals that stem from particles or
co-localization (Lehmann et al. 2010).
Transmission electron microscopy (TEM)
MDDCs were ﬁxed with buffered 2.5% glutaralde-
hyde (Agar Scientiﬁc Ltd, Plano GmbH, Wetzlar,
Germany), 1.0% osmium tetroxide (Simec, Zoﬁngen,
Switzerland), and 0.5% uranyl acetate (Fluka Chemie
GmbH, Sigma-Aldrich, Buchs, Switzerland). Subse-
quently, cells were dehydrated in a graded series of
ethanol (70, 80, 96, and 2  100%) and gradual
replacement of ethanol by propylene oxide before
inﬁltrating and embedding the cells in epoxy resin
was performed. Ultrathin sections were obtained uti-
lizing an ultramicrotome (Reichert, Austria), before
transfer onto 200-mesh uncoated copper grids
stained with uranyl acetate and counterstained with
lead citrate. TEM was performed with a Philips
300 TEM at 60 kV (FEI Company Philips Electron
Optics, Zurich, Switzerland). Cells from at least three
different donors were analyzed. For qualitative anal-
ysis sections of 5–10 cells were analyzed per donor.
Statistical analyses
Unless indicated otherwise, data are presented as
mean ± SEM of experiments from 3–8 different
experiments/donors. Unpaired Student’s t-tests
were applied to calculate signiﬁcances. Differences
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were considered as statistically signiﬁcant at a value
for p < 0.05. Data were analyzed using GraphPad
Prism software.
Results
PVA-SPION uptake by MDDCs and modulation by
concomitant LPS exposure
To quantify PVA-SPION uptake, MDDCs were trea-
ted during 12 h with 5–100 mg/ml PVA-SPIONs with
or without concomitant LPS (Figure 1). FACS anal-
yses showed that SPION uptake byMDDCs occurred
dose-dependently, as measured by an increase in delta
mean ﬂuorescence intensity (Figure 1A). Concurrent
LPS exposure decreased SPION uptake by MDDCs
at concentrations greater than 20 mg/ml by a known
phenomenon related to LPS-dependent MDDCmat-
uration that decreases the ability to endocytose anti-
gen (Figure 1B). Based on these dose-ranging studies
and importantly to avoid maturation (and LPS)-
dependent decrease of nanoparticle uptake by
MDDCs, we performed subsequent experiments
with PVA-SPIONs only with the two concentrations
of 10 and 20 mg/ml.
Morphological analyses and quantiﬁcation of SPION
uptake by MDDCs
To further characterize the fate of PVA-SPIONs
taken up by MDDCs, morphological analyses were
performed by TEM and LSM (Figure 2). TEM
enabled identiﬁcation of electron-dense iron cores
(10 nm in diameter), but not PVA shells, of individual
PVA-SPIONs (Figure 2A). In TEM analyses of
MDDCs, intra-cellular PVA-SPIONs were sur-
rounded by a membranous structure corresponding
to the endosomal compartment (Figure 2B and
insert). Treatment of MDDCs with cytochalasin D
to inhibit actin-dependent endocytosis resulted in
extra-cellular accumulation of PVA-SPIONs and
a sharp decline of intra-cellular PVA-SPIONs
(Figure 2C and insert). LSM was performed on
MDDCs to further characterize uptake, intra-
cellular localization, and association of PVA-SPIONs
with the endosomal compartment (Figure 2D–I).
Cytochalasin D treatment of MDDCs resulted in
fewer cytoplasmic processes through inhibition of
actin polymerization and strongly reduced particle
uptake, as shown both in TEM and LSM images
(Figure 2B, D, E, G, I).
Since conventional LSM is not able to resolve
individual PVA-SPIONs (showing diameters of
100 nm and smaller) which are located below the
theoretical limit of resolution of light micro-
scopy (around 200 nm), counted particles and
co-localization were expressed as particle events
and co-localized events, respectively with events refer-
ring to the number of voxel emitting signals that stem
from particles or co-localization (expressed as number
of particle events in Figure 3; see also Materials and
methods section). Several salient ﬁndings emerged
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Figure 1. Flow-cytometric (FACS) analysis of PVA-SPION uptake by MDDCs. MDDCs were incubated during 12 h with different
concentrations of Oregon green 488-labelled PVA-SPIONs in the presence or absence of LPS. (A) FACS histogram plots gated on theMDDC
population (see Figure 4a or Figure 5a) in the absence (upper panel, LPS ) or presence (lower panel, LPS +) of LPS with 0 mg/ml (grey solid
curve), 10 mg/ml (faint grey line), 20 mg/ml (light grey line), 40 mg/ml (dark grey line), and 100 mg/ml (black line) of SPIONs. One representative
graph of three independent experiments (different donors) is shown. (B) SPION uptake by MDDCs as delta mean ﬂuorescence intensity
(measured MFI in MDDCs treated with PVA-SPIONs minus background MFI in untreated MDDCs) at different SPION concentrations
tested. Average values (± SEM) of three experiments that originate from three different donors are shown.
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from quantitative LSM analyses (Figure 3). First,
there was a signiﬁcant dose-dependent increase of
intra-cellular particle events in MDDCs (no cytocha-
lasin D) when increasing the PVA-SPION concen-
tration from 10–20 mg/ml (Figure 3; intra-cell. in Cyt
D ). Second, co-localization of particle events and
endosomal compartment (transferrin receptor stain-
ing) remained constant at both concentrations tested
(Figure 3; co-local. in Cyt D ), but proportionally
more events were co-localized (total intracellular par-
ticle events/co-localized events) with 10 mg/ml (61%)
than for 20 mg/ml (43%) (data not shown). Third,
treating MDDCs with cytochalasin D led to signiﬁ-
cantly reduced intra-cellular and co-localized particle
events, but increased extra-cellular particle events, i.e.
corresponding to particle aggregates attached to the
outer cell surface (Figure 3; extra-cell. Cyt D +).
A degree of extra-cellular particle aggregation may
have led to a reduced total number of particle (ﬂuo-
rescence) events counted, as compared to ﬂuores-
cence emitted by non-aggregated particles. It is
necessary to emphasize that extra-cellular particle
events counted in cytochalasin D-treated cells com-
prise only particles attached to the cellular surface and
therefore do not represent the complete amount of
particles restricted from entering the cells (hence the
smaller amount of overall particle events counted in
cytochalasin D-treated cells).
In summary, TEM and LSM studies showed that
PVA-SPIONs were endocytosed in a dose-related
manner, predominantly by an actin-dependent pro-
cess. Very few particles entered MDDCs by other,
non-actin-dependent processes, as shown by the
number of particle-related events that occurred after
D
A B
Cyt-D – Cyt-D +
C
Cyt-D 0 10 20– – –+ + +
XY
XZ
XZ
XY
D´ E´ F´ G´ H´ I´
E F G H I
SPIONs [μg/ml]
Figure 2. Visualization of PVA-SPION uptake by MDDCs with TEM and LSM as described in the Methods section. MDDCs were treated
with PVA-SPIONs (10 and 20 mg/ml) during 4 hours and subsequently incubated with Transferrin Alexa 633 (100 mg/ml; marker for
lysosomes) for 20 min either in the absence or presence of cytochalasin D (Cyt-D; 10 mg/ml) added to the cell cultures 30 min before particle
exposure as previously described (Thiele et al. 2001). (A–C) TEM pictures of individual PVA-SPIONs (A), MDDCs without (B) and with (C)
cytochalasin D pre-treatment prior to incubation with PVA-SPIONs. Higher magniﬁcation inserts show PVA-SPIONs intra-cellularly in
lysosomes (B), or extra-cellularly (C). (D-I) LSM pictures of MDDCs treated with Oregon green labelled PVA-SPIONs (D and E, 0 mg/ml; F
and G, 10 mg/ml; H and I; 20 mg/ml) during 4 h with transferrin Alexa 633 for the last 20 min either in the absence (D, F, and H) or presence (E,
G, and I) of cytochalasin D.Micrographs (D-I) show the localization of PVA-SPIONs (green), transferrin receptor (blue), and nuclei (white) in
different experimental conditions. Actin (red) staining (D’-I’) facilitated detection of intra-cellular (asterisks) and extra-cellular (arrowheads)
localization of SPIONs. xy-projections (top panels) and xz-projections (lower panels) were obtained frommultiple consecutive optical sections.
One representative experiment from three experiments is shown.
Nanoparticles modulate function of DCs 7
N
an
ot
ox
ic
ol
og
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
D
R 
Ba
rb
ar
a 
Ro
th
en
 o
n 
01
/1
7/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
cytochalasin D pharmacological blockade. Depend-
ing on their initial concentration, between 40 and
60% of the intra-cellular PVA-SPIONs trafﬁcked
to the endosomal compartment, as shown by
co-localization studies.
Phenotypic changes, apoptosis, and cell death in
MDDCs treated with PVA-SPIONs
FACS analyses were performed to assess the surface
phenotypic changes on MDDCs following exposure
to 10 and 20 mg/ml SPIONs with or without concur-
rent LPS (Figure 4). These PVA-SPION doses were
chosen because LPS treatment did not alter the PVA-
SPION uptake at such concentrations (see above
and Figure 1). The gating strategy utilized is shown
with a representative experiment (Figure 4A). The
frequency of MHC class II and co-stimulatory mol-
ecule CD80/CD86 expression increased with LPS
treatment but was not affected by PVA-SPION treat-
ment except for cell cultures exposed to 10 mg/ml
PVA-SPIONs that showed lower MHC II expression
with and without LPS activation (Figure 4B).
Furthermore, as a marker of maturation, CD83
remained unchanged when MDDCs were treated
with PVA-SPIONs, both with (consistent maturation
of DCs) and without LPS (Figure 4B). The frequen-
cies for CD11c+ BDCA-1+ myeloid DC (mDC) or
the fraction of CD123+ BDCA-2+ plasmacytoid
(pDC) were not altered by PVA-SPION treatment
(Figure 4B). Importantly, no excess apoptosis
(Annexin V) or necrosis (propidium iodide) was
observed in MDDCs treated with PVA-SPIONs
(Figure 4B). Treatment with PVA-SPION concen-
trations up to 50 mg/ml did not affect MDDC phe-
notype or viability (data not shown).
In summary, these data provide evidence that in
treated MDDCs, PVA-SPIONs did not induce
maturational or activation changes (except a lower
frequency of MHC II+MDDCs treated with 10 mg/ml
PVA-SPIONs), alter the mDC/pDC balance, or
cause apoptosis/cell death. Furthermore, responses
of MDDC to LPS activation remained intact during
treatment with PVA-SPIONs.
Exposure to PVA-SPIONs: functional changes in
MDDCs
A further series of experiments investigated whether
MDDCs underwent functional changes by PVA-
SPION treatment. To assess the capacity of MDDCs
for antigen uptake and antigen processing, two ﬂuo-
rochrome compounds coupled to ovalbumin (OVA)
as a carrier protein were utilized: OVA-Alexa 647 and
DQ-OVA as surrogate markers for antigen uptake and
antigen processing, respectively (Wikstrom et al.
2006; von Garnier et al. 2007). The FACS gating
strategy utilized to determine these parameters is
detailed in Figure 5A. Surface expression of MHCII,
a prerequisite for antigen-presentation, was also
determined simultaneously during incubation with
the above ﬂuorochrome compounds.
Treatment with PVA-SPIONs did not alter the
capacity of MDDCs to endocytose antigen, but
down-regulated the ability for antigen processing at
higher PVA-SPION concentration (20 mg/ml), both
with and without concomitant LPS exposure
(Figure 5B, left and centre panels). Moreover, during
the time course (0–120 min) performed for antigen
uptake and antigen processing experiments, SPIONs-
treated MDDCs showed less LPS-induced MHCII
surface expression (Figure 5B, right panels).
To determine how changes in antigen processing
and MHCII expression impacted on downstream
immune responses, an in vitro CD4+ T cell stimula-
tion assay was utilized as described in the Methods
section (Figure 6). Following treatment with PVA-
SPIONs, MDDCs were co-cultured with autologous
CD4+ T cells to assess the responses to LPS, antigen
120
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20 μg/ml SPION
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Figure 3. Fate of PVA-SPIONs incubated with cytochalasin D-
treated (Cyt D +) or –untreated (Cyt D ) MDDCs as determined
by LSM. MDDCs were treated with PVA-SPIONs (10 and 20 mg/
ml) during 4 h and subsequently incubated with Transferrin Alexa
633 (100 mg/ml; marker for lysosomes) for 20 min either in the
absence or presence of cytochalasin D (Cyt-D; 10 mg/ml) added to
the cell cultures 30 min before particle exposure as previously
described (Thiele et al. 2001) PVA-SPIONs were localized either
extra-cellular (extra-cell.), or intra-cellular (intra-cell.), and co-
localized (co-local.) with transferrin receptor staining for the latter.
Quantiﬁcation was performed as described in the Methods section.
Bar graph represents the mean (± SEM) from four experiments.
For statistics, *p < 0.05; **p < 0.005; ***p < 0.0005; and ns,
non-signiﬁcant as determined by unpaired Student’s t-test com-
paring cytochalasin D-untreated (Cyt D ) vs. cytochalasin-
treated (Cyt D +) MDDCs, except for “intra-cell” and
“co-local” in untreated MDDCs (Cyt D ), where 10 mg/ml vs.
20 mg/ml SPIONs were compared.
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(tetanus toxoid), or both (Figure 6). Both PVA-
SPION concentrations signiﬁcantly reduced CD4+
T cell proliferation induced by LPS, tetanus toxoid,
or both combined (Figure 6). As T cell stimulations
were reduced for both PVA-SPION concentrations,
we determined cytokine levels for 10 and 20 mg/ml -
PVA-SPIONs (Figure 7). Cytokines measured in
supernatants obtained from co-culture experiments
(i.e. 10 and 20 mg/ml PVA-SPION-treated MDDCs
and CD4+ T cells) in the presence LPS and tetanus
toxoid showed a signiﬁcantly decreased release of
IL-1b, IL-5, IL-6, IL-12p70, TNF-a, and IFN-g,
but increased production of IL-10 (Figure 7).
Discussion
Development of biomedical nanoparticles for future
diagnostic and therapeutic applications is currently
an area of intense research in nanotechnology.
Nanosized formulations can be speciﬁcally designed
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Figure 4. Surface phenotype, apoptosis, and cell death of MDDCs following treatment with PVA-SPIONs during 12 h. (A) Representative
experiment showing gating strategy based on relevant isotype controls (IgG, and ﬁlled histogram curves) to determine frequency of expression
for surface markers: activation (CD80, CD86), maturation (CD83), myeloid or conventional DCs (BDCA1/CD11c), plasmacytoid DCs
(BDCA2/CD123). (B) MDDCs were treated with 0, 10, and 20 mg/ml PVA-SPIONs in the absence (open bars, LPS ) or presence (ﬁlled
bars, LPS +) of LPS as detailed in the methods section. Bar graphs (average ± SEM) show the frequency of surface marker expression,
apoptosis (Annexin V), and cell death (Propidium iodide). Results from ﬁve experiments are shown and expressed as mean (± SEM). ns, non-
signiﬁcant and *p < 0.05 as determined by unpaired Student’s t-test comparing PVA-SPION-untreated vs. PVA-SPION-treated MDDCs.
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to either stimulate or inhibit immune responses, or
evade recognition by the immune system altogether.
Nanomaterials administered to the organism will
potentially encounter antigen-presenting cells, espe-
cially DCs, that may undergo functional changes
with profound consequences on the initiation and
subsequent regulation of immune responses to nano-
particles or their payload. Alteration of immune
responses by nanoparticles may represent a form of
“nano-immuno-toxic” effect that may seriously
undermine future efforts to develop novel therapeutic
or diagnostic approaches.
Utilizing prototypic ﬂuorochrome-labelled model
PVA-SPIONs previously evaluated in several pre-
clinical studies, we herein provide data derived
from in vitro studies of DCs treated with such nano-
particles (Petri-Fink et al. 2005; Cengelli et al. 2006;
Hellstern et al. 2006; Petri-Fink and Hofmann 2007;
von Zur Muhlen et al. 2007; Butoescu et al. 2008;
Petri-Fink et al. 2008; Butoescu et al. 2009;
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Figure 5. Antigen-uptake, antigen-processing, and MHCII expression of MDDCs treated with PVA-SPIONs during 12 h. Endocytotic
capacity (antigen uptake) and antigen processing were measured by incubation with a variety of ﬂuorescent conjugates, as previously described
(Wikstrom et al. 2006; von Garnier et al. 2007). OVA-Alexa Fluor 647 (Alexa-OVA) was utilized to measure endocytotic capacity and DQ-
OVA to determine antigen processing. MDDCs were incubated during a time course of 0–120 min at 37C or on ice (controls) to measure
antigen uptake and processing. (A) Gating strategy consists in an initial FSC/SSC gate (panel one from left), isotype-controlled gate for
CD11c+/BDCA1+ DCs (panel two from left), and Alexa-OVA+ (antigen uptake) or DQ-OVA+ (antigen processing) cells (panel three and four
from the left). Negative controls (solid curves) in the histogram plots were derived from cells kept at 4C during the length of the experiment.
(B) Bar graphs (white, 0 mg/ml; grey, 10 mg/ml; and black 20 mg/ml PVA-SPIONs) show the capacity for antigen-uptake (left panels, Alexa-
OVA), antigen processing (middle panels, DQ-OVA), and expression of MHCII (right panels, MHCII). Results from ﬁve experiments are
shown and expressed as average Delta mean ﬂuorescence intensity (D MFI = measured MFI  background of isotype control MFI)
values ± SEM. *p < 0.05; **p < 0.005; and ***p < 0.0005 as determined by unpaired Student’s t-test comparing PVA-SPION-treatedMDDCs
to untreated MDDCs.
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Montet-Abou et al. 2010). Other research groups have
previously investigated effects of nanoparticles on DC
activation and maturation, but to our knowledge, our
data are the ﬁrst to show that prototypic biomedical
nanoparticles, such as SPIONs, are able to modulate
immune responses by affecting DC-dependent anti-
gen-processing and antigen-presentation. Broos et al.
(2010) recently showed that 200 nm-sized biodegrad-
able poly(g-glutamic acid) (g-PGA) nanoparticles
activated immature MDDCs through increased
expression of co-stimulatory molecules and secre-
tion of inﬂammatory chemokines and cytokines; in
MDDCs obtained from grass pollen allergic indivi-
duals, g-PGA nanoparticles increased allergen-speciﬁc
IL-10 production. A fullerene derivative containing an
entrapped Gadolinium atom (Gd@C82(OH)22) acti-
vated DCs and in mice enhanced ovalbumin-speciﬁc
Th1 responses (Yang et al. 2010). Furthermore,
Vallhov et al. (2007) compared the effects of different
sized mesoporous silica particles (270 nm 2.5 mm) on
the viability and the activation markers of human DCs
and found that the smaller particles affected the cells
to a minor degree compared to the larger particles.
The most salient ﬁndings from our work showed
that in vitro treatment of MDDCs with PVA-
coated SPIONs did not affect maturation, activation,
or viability of DCs, but modulated their capacity to
process and present antigen, leading to decreased
T cell stimulation and less pro-inﬂammatory cytokine
release.
In the ﬁrst part of our studies we provided advanced
imaging data obtained from TEM and LSM showing
that MDDCs endocytosed PVA-SPIONs mainly by
an actin-dependent mechanism, with subsequent traf-
ﬁcking of PVA-SPIONs to the endosomal compart-
ment. Although the number of intra-cellular particles
was dependent on the PVA-SPION concentration,
localization to the endosomal compartment was con-
stant and unaffected by PVA-SPION concentration.
Furthermore, particle uptake was almost completely
blocked when cells were treated with cytochalasin D,
an inhibitor of actin polymerization. Since there is no
data yet available on SPION uptake by DCs, our
in vitro data should be compared to similar studies
performed with different cell types. As an example,
Landmark et al. (2008) exposed a carcinoma cell line
to organic-coated super-paramagnetic iron oxide
nanoparticles and observed frequent uptake within
intracellular vesicles. Furthermore, due to a high
autocorrelation between intra-cellular zinc and iron,
the authors postulated an uptake mechanism through
clathrin-coated pits, because zinc is a transmission
metal typically associated with this mechanism of
endocytosis. Since uptake via clathrin-coated pits is
an actin-driven process, these ﬁndings are in accor-
dance with our results in DCs. Although LSM data
provided only a 40–60% co-localization rate between
PVA-SPIONs and the transferrin receptor ﬂuores-
cence, our TEM studies failed to detect SPIONs
localized freely in the cytoplasm (outside endosomes),
nor in the nucleus or in mitochondria. This ﬁnding is
of particular importance since we can assume that the
PVA-SPIONs utilized in our study are unlikely to
interact with genomic DNA in the nucleus or with
respiratory chain components in mitochondria and
are therefore less likely to induce genetic changes,
inﬂammatory effects, and/or oxidative stress. Further-
more, in particle-exposed cell cultures we failed to
detect an increase in cell death or apoptosis that
would be an inevitable outcome of enhanced cyto-
toxicity. In an in vitro study utilizing a triple cell
co-culture model of the lung mucosa (consisting of
epithelial A549 cells, human monocyte-derived
macrophages, and DCs), 25 nm gold nanoparticles
were freely distributed within the cytoplasm and cell
nuclei (Rothen-Rutishauser et al. 2007). Contrasting
with other types of nanoparticles (polystyrene, TiO2)
that were detected intra-cellular only within mem-
brane bound vesicles, gold nanoparticles induced an
enhanced release of TNFa in triple cell co-cultures.
In-depth analysis assessing intracellular distribution
of PVA-SPIONs will eventually be necessary, e.g. by
utilizing advanced imaging methods such as electron
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Figure 6. CD4+ T cell stimulatory capacity ofMDDCs treated with
PVA-SPIONs.MDDCs were treated with 10 mg/ml and 20 mg/ml of
PVA-SPIONs during 12 h in the absence or presence of LPS. As
detailed in the methods section, MDDCs were subsequently incu-
bated with autologous CD4+ T cells to determine antigen-
speciﬁc (tetanus toxoid) and/or LPS-dependent (LPS) CD4+
T cell proliferation. Co-cultures were performed for ﬁve days
and pulsed with 0.5 mCi [3H] thymidine during the last 16 h.
For T cell control, culture was performed without MDDCs to
determine background T cell proliferation. Results from ﬁve experi-
ments are shown and expressed as average values ± SEM. For
statistics, *p < 0.05 and **p < 0.005 as determined by unpaired
Student’s t-test comparing PVA-SPION-exposed to non-exposed
MDDCs. CPM: counts per minute.
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energy loss spectroscopy or tomography EM to
conclusively determine if PVA-SPIONs have the
potential to enter mitochondria and/or cell nuclei
(Rothen-Rutishauser et al. 2007). Another important
issue, i.e. investigation of SPION biodegradation in
DCs, was beyond the scope of our present work; but
several lines of evidence in the literature suggest that a
certain degree of SPION degradation is likely to occur
via the lysosomal pathway: A study on murine bone
marrow macrophages showed that opsonized albumin
and dextran-coated SPIONs taken up by receptor-
mediated endocytosis were found in vesicles resem-
bling terminal lysosomes (Schulze et al. 1995).
Another study using mesenchymal stem cells
exposed to dextran-coated SPIONs found particle-
containing endosomes to fuse with lysosomes, leading
to degradation of SPIONs into soluble Fe(III) within
the lysosomes (Arbab et al. 2005). Several toxicolog-
ical studies have demonstrated over the last decade
that combustion generated nanoparticles readily gen-
erate oxidative stress through reactive oxidative spe-
cies (ROS) and inﬂammation (Donaldson et al. 2005;
Xia et al. 2006;Warheit et al. 2007). In addition to the
fact that some nanoparticles are able to directly inter-
act with genomic DNA, it has been shown that
oxidative stress may play a major role in particle-
induced DNA damage that can be prevented by
antioxidants and scavengers of ROS (Donaldson
et al. 2003; Tsoli et al. 2005). However, detailed
molecular mechanisms involved in the hallmark cel-
lular responses to genotoxic effects are currently not
known and require meticulous clariﬁcation in the
future.
The decreased antigen processing capability of
MDDCs with PVA-SPION treatment may be partly
explained by the fact that DCs have a limited proteo-
lytic capacity in their lysosomes that is enhanced with
maturation (Trombetta et al. 2003; Trombetta and
Mellman 2005). A central question when investigat-
ing interactions between cells and nanoparticles is the
colloidal behaviour of the latter, as this will ultimately
determine how cells “sense” particles and respond to
these. Though we cannot exclude a certain degree of
agglomeration of PVA-SPIONs localized within the
lysosomes occurred prior to endocytosis, previous
investigations by Petri-Fink and Hofmann (2007)
concluded that the cell culture medium (i.e.
DMEM or RPMI) had no inﬂuence, but addition
of serum to the cell culture medium signiﬁcantly
reduced the agglomeration rate of PVA-SPIONs.
Based on these data, utilization of RPMI plus FCS
as culture medium in our in vitro experiments reduced
agglomeration rates of PVA-SPIONs. Once endocy-
tosed, PVA-SPIONs may simply undergo a concen-
tration effect within lysosomes. Although electron
micrographs showed PVA-SPION agglomerates in
the lysosomes, we have not investigated whether par-
ticles underwent speciﬁc structural changes following
endocytosis. Although it will be crucial for the devel-
opment of nanoparticles destined for speciﬁc applica-
tions to determine changes that particles may undergo
within different intra-cellular compartments (e.g.
lysosomes), this is beyond the scope of the current
report and will require clariﬁcation in future work.
In the second part of our studies, ﬂow cytometric
analyses provided evidence that PVA-SPIONs did not
affect MDDC maturation, activation, frequencies of
mDC and a minor fraction of pDC, or cell viability. In
contrast, SPIONs modulated MDDC function by
decreasing antigen processing, expression of MHCII
and the capacity to stimulate autologous CD4+ T cells
in vitro. These ﬁndings suggest that PVA-SPIONs
possess an intrinsic capacity for immune-modulation
and may potentially provide a form of tolerance induc-
tion by affecting DC function. There are several lines
of evidence in the literature demonstrating that other
types of nanoparticles may induce a degree of desirable
immune-suppression: synthetic peptide dendrimers
inhibited experimental allergic encephalomyelitis,
allergen-loaded nanoparticles and dendrimers down-
regulated allergic reactions to environmental and food
allergens, and a fullerene derivative polyhydroxy C60
prevented type I hypersensitivity reactions (Scholl et al.
2004; Balenga et al. 2006; Gomez et al. 2007, 2008;
Wegmann et al. 2008). Size, surface charge and coat-
ing may confer to a nanoparticle its intrinsic properties
that may lead to immune-suppression. By which
mechanisms these effects occur and which immune
cells are involved in the process of such an immune-
modulation is unclear at present. We herein provide
evidence that part of this mechanism may operate via
functional modulation of DCs, i.e. by modifying the
way that antigen is handled. This may be affected at
several levels: First, although our data did not show any
changes in antigen uptake by SPION exposure, several
other studies showed that this parameter was affected
by nanoparticle exposure in phagocytic cells such as
macrophages (Moss andWong 2006). Second, antigen
processing as measured with the surrogate marker DQ-
OVA, was decreased by SPION exposure. We have
previously shown that DQ-OVA-related ﬂuorescence
correlates with T cell stimulatory capacity in mouse
studies (Wikstrom et al. 2006). Third, expression of
MHCII, a prerequisite for efﬁcacious antigen proces-
sing, was down-regulated by SPIONs. Consequently,
DC-dependent stimulation of autologous CD4+
T cells in the presence of antigen (tetanus toxoid),
LPS, or both was reduced by treatment with SPIONs.
Cytokine levels measured in T cell simulation assays
substantiated the above observations with the ﬁnding
Nanoparticles modulate function of DCs 13
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that PVA-SPION-treated MDDCs induced signiﬁ-
cantly lower production of pro-inﬂammatory cyto-
kines. As an exception IL-10, a cytokine known for
its anti-inﬂammatory effects, was elevated following
PVA-SPION treatment relative to the other pro-
inﬂammatory cytokines analysed. Thus PVA-SPIONs
may modulate DC function through an intrinsic anti-
inﬂammatory effect and it is unlikely that the observed
shift in the pro-/and anti-inﬂammatory cytokine pro-
ﬁles is due to a generally reduced protein synthesis
and/or cytokine production.Moreover, the ﬁnding that
IFNg production was strongly reduced further sup-
ports that an anti-inﬂammatory effect of PVA-SPIONs
may be present. IFNg is a type-II interferon secreted by
several immune cells (DCs, Th1, T cells, and NKT)
with anti-viral, anti-tumor, and immunoregulatory
effects induced through regulation of about 30 genes
(Schroder et al. 2004). IFNg regulates class II antigen
presentation through the expression of key genes
related to MHCII-dependent antigen-presentation:
a1, a2, b1, b2 MHC II chains (constituents of the
heterodimeric MHC II complex), invariant Ii chain
(transmembrane chaperone that trafﬁcs MHC II from
the endoplasmic reticulum to the MHC II endosomal
compartment), DMA andDMB (dimers formingDM,
a protein that removes CLIP from the peptide-
binding cleft of MHC II so that it is accessible for
peptide loading), Cathepsins B, H, L (lysosomal pro-
teases that produce peptides for loading on MHC II),
and Class II transactivator (transactivator regulating
the transcription of key genes involved in MHC II
expression, including constituents of the MHC II
complex, Ii chain, and DM) (Lafuse et al. 1995;
Lah et al. 1995; Wolf and Ploegh 1995; Mach et al.
1996). Therefore, lower levels of IFNg release
observed in the co-culture assays may reﬂect the
reduced ability of PVA-SPION-treated DCs to present
antigen via the MHCII pathway and activate CD4+
T cells.
Finally, reduced capacity of MDDCs to process
antigen, secrete cytokines, and stimulate T cells may
be partly related to the polymer coating PVA known
to bind proteins through hydrogen-bonding interac-
tions (Aggarwal et al. 2009). The extent of protein
adsorption is related to its structure and net charge,
i.e. negatively charged nanoparticles bind proteins
with isoelectric points greater than 5.5, whereas pos-
itively charged particles bind proteins with isoelectric
points less than 5.5 (Aggarwal et al. 2009). The zeta
potential (surface charge) of PVA-SPIONs utilized
was slightly positive, therefore binding of proteins
with isolelectric points > 5.5 involved in antigen-
processing pathways, such as Cathepsin B, H,
L1 and DMBmight have affected antigen-processing,
presentation and T cell stimulation. Binding of the
antigen tetanus toxin (isoelectric point 5.8) utilized in
the experimental set-up may sequester antigen and
interfere with its downstream processing and memory
immune responses. Furthermore, interference with
inﬂammatory mediators, such as cytokines, may
occur and contribute to strongly decreased levels of
IFNg (isoelectric point 9.5) observed in MDDCs
treated with PVA-SPIONs. Whether the extent of
PVA-SPION-dependent binding of proteins or
enzymes is sufﬁcient to affect DC function is
unknown at present and beyond the scope of this
study, but will ultimately require careful investigation
to understand the immune effects of biomedical
nanoparticles.
In summary, data herein reported show to our
knowledge for the ﬁrst time that polymer-coated
PVA-SPIONs exerted a certain degree of immune-
modulation by inhibition of MDDC function. These
effects were mediated by modulation of the antigen-
processing and antigen-presentation capacity of
MDDCs, resulting in reduced CD4+ T cell activa-
tion and altered cytokine proﬁles towards an anti-
inﬂammatory phenotype dominated by IL-10
production. The observed functional changes indi-
cate that DCs may revert to a more unresponsive and
immature-like state (low capacity for T cell stimu-
lation) with PVA-SPION treatment. Although such a
functional DC phenotype may be beneﬁcial for the
induction of tolerance in various clinical conditions
such as autoimmune or allergic disease, conse-
quences of altered immune responses related to
nanoparticle treatment will require meticulous clar-
iﬁcation. Hence, future strategies to design biomed-
ical nanoparticles for speciﬁc therapeutic and
diagnostic clinical applications need to take into
account their potential effects on key immune cells
and downstream immune responses.
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